Behind every puff of a vape, there's a battery. >> Oh, look at that disposable vape. And this might be the guy that knows that better than anyone out there.>> There is a lithium ion cell that is actually completely fully rechargeable. This ebike battery. >> When we first met Chris Dole, he was using the batteries from disposable vapes to power an ebike.Now he's taken the experiment to a whole new level. Chris collected 500 vapes that local shops were trying to get rid of and wired them up to power everythin ...

Core Viewpoint - MediPharm Labs Corp. is preparing for its Annual and Special Meeting of Shareholders on June 16, 2025, emphasizing the importance of shareholder support for its Board of Directors and strategic direction amidst a challenge from a dissident shareholder [1][2][6]. Financial Performance - In 2024, MediPharm reported a 27% year-over-year increase in net revenue and improved gross profit margin from 18% in 2023 to 31% [5]. - The company's Adjusted EBITDA loss narrowed by $8.3 million to $1.9 million in 2024 compared to the previous year, with expectations of reaching positive Adjusted EBITDA soon [5]. Strategic Developments - MediPharm has undergone a strategic revitalization, including the acquisition of VIVO Cannabis in March 2023, which has opened new international markets and contributed approximately $10 million in annual revenue from its Beacon brand in Australia [12][13]. - The company has streamlined operations, focusing on strategic business lines and reducing operating expenses by half through synergies from the VIVO acquisition [11][13]. Governance and Shareholder Engagement - The Board of Directors recommends shareholders vote using the GREEN proxy to support its nominees, highlighting concerns about the qualifications of dissident nominees from Apollo Technology Capital Corp. [2][6][16]. - MediPharm emphasizes its commitment to good governance practices, including an independent Chair and key committees, to enhance shareholder value [20][21]. Market Position and Future Outlook - MediPharm's product mix includes various cannabis products, with international sales exceeding 50% of revenues in recent quarters, positioning the company for growth in the medical cannabis sector [15]. - The company believes it has established a solid foundation for future growth and is committed to ongoing enhancements in governance and operational strategies [28][27].

Core Insights - Philip Morris is targeting a 13% to 15% growth in EPS for the year, reaffirming its guidance in a recent press release [2] - The company has been undergoing a smoke-free transformation for over 10 years, achieving its strongest growth since 2011, excluding the post-pandemic recovery [2] - Despite focusing on smoke-free products, the company is still seeing positive volume growth across its total business [3] Company Strategy - The emphasis is on transitioning from combustible products to smoke-free alternatives, including heat-not-burn and vaping products [3] - The company is committed to maintaining pressure on its combustible business while promoting smoke-free innovations [3]